Regeneron beats Q2 2026 estimates with non-GAAP EPS $14.29 (+11% YoY) and revenue $4.3B (+17% YoY), raises 2026 gross margin guidance and narrows R&D and SG&A ranges
https://finviz.com/stock?t=REGN&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.